We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.
The local start-up is advancing a novel multi-valent and multi-specific antibody platform with exquisite potency and efficacy.
Radiant received a seed investment from FACIT’s Compass Rose Oncology Fund.
FACIT is proud to have been an early supporter of Replica through a Prospects Oncology Fund investment in June 2020.
Having recently announced several collaborations following the closing of a financing round with Nina Capital, Replica has significant momentum behind it.
FACIT’s Prospects Fund invests in two emerging Ontario diagnostics for colorectal and prostate cancers
Early-stage capital drives commercialization and clinical validation in Province.
Both innovations were previous finalists in FACIT’s 2021 Falcons’ Fortunes pitch competition.
The capital will enable Turnstone to advance its platform and pipeline of next-generation oncolytic virus.
The start-up seeded by FACIT in collaboration with several Ontario research institutes continues to deepen its roots in Canada and grow on both sides of the border.
Ontario start-up to commercialize smart nanomedicine technology for brain cancer
FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund.
FACIT Features: Notch Therapeutics Closes $85M USD Series A for Renewable Stem Cell-Derived Cancer Immunotherapies
Notch is a Canadian biotech incubated by Ontario-based Centre for Commercialization of Regenerative Medicine (CCRM)
The financing is one of the largest Series A financing round in Canadian biotech history, notably at a time of heightened interest by Ontario in commercializing homegrown intellectual property.